AtaCor Medical Initiates ASCEND EV Clinical Study
AtaCor Medical, Inc. has embarked on an exciting journey by initiating its ASCEND EV clinical study, targeting significant advancements in cardiac rhythm management. This innovative study focuses on their Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System, which is aiming to meet critical healthcare needs effectively.
Key Features of the Atala™ Lead
The Atala™ lead is designed with a novel concept centered on extravascular methodology, enhancing the delivery of life-saving therapies. It aims to provide reliable recognition of heart issues, antitachycardia pacing (ATP), and shocks, all while working outside of traditional vascular pathways.
Initial clinical cases have shown promising results. Physicians reported successful sensing and defibrillation when using the Atala™ lead across various commercially available ICDs, marking a significant advancement in treatment options for patients experiencing life-threatening ventricular tachyarrhythmias.
Clinical Updates and Future Directions
This study is notable as it records the first-time permanent installation of AtaCor's EV-ICD Lead System, setting a precedent in the realm of cardiac care. The system facilitates a streamlined approach, allowing for ATP and shock delivery in a single procedure without the need for entering the heart's vascular system.
Dr. Shephal Doshi, a key investigator in the ASCEND EV study, expressed his enthusiasm for these early cases, noting that devices like the Atala™ lead can uplift standards for cardiac rhythm management. His insights showcase the potential for significant benefits that the extravascular approach offers to patients while preserving heart integrity.
Commitment to Innovation in Cardiac Care
The Chief Medical Officer of AtaCor Medical, Dr. Martin Burke, emphasized the company’s commitment to transforming cardiac rhythm management. He praised the collaborative efforts of the AtaCor team and its physician partners, highlighting their determination to achieve this critical milestone. Furthermore, Dr. Burke pointed out the intention to broaden the study by adding more clinical sites in the upcoming months, further expanding the reach of their innovative technology.
The AtaCor EV-ICD Lead System is currently in a developmental phase and is designated exclusively for investigational purposes. Until approval, the system will not be available for sale.
About AtaCor Medical
AtaCor is dedicated to pioneering advancements in cardiac rhythm management. With a strong focus on developing extravascular leads and deployment systems, the company addresses the risks, costs, and limitations associated with conventional transvenous leads. Their mission centers on ensuring safe and efficient cardiac care for patients. For more information about AtaCor Medical and their innovative solutions, please visit www.atacor.com.
Frequently Asked Questions
What is the purpose of the ASCEND EV clinical study?
The ASCEND EV study aims to evaluate the safety and performance of AtaCor's Extravascular ICD Lead System in relation to established transvenous ICD systems.
What are the main features of the Atala™ lead?
The Atala™ lead is designed to provide reliable sensing, ATP, and shock therapies through an extravascular approach, thus minimizing invasion into the vascular system.
Who is leading the ASCEND EV study?
The study is being led by Dr. Shephal Doshi, who has highlighted the advancements in cardiac rhythm management represented by this innovative device.
What should we know about the installation process of the Atala™ lead?
The Atala™ lead can be implanted using a streamlined method, which facilitates the entire process in a single procedure without entering the heart.
How is AtaCor planning to advance its clinical study?
AtaCor is looking to expand the clinical study by adding more sites in the upcoming months to gather additional data on the Atala™ lead's effectiveness.
